Astonea Labs Limited - IPO
SMEAstonea Labs IPO Details
Astonea Labs IPO Subscription
Astonea Labs IPO Application Wise Breakup
Astonea Labs IPO Dates
- 27 May 2025Opening dateOPD
- 29 May 2025Closing dateCOD
- 30 May 2025Basis of AllotmentBOA
- 02 Jun 2025Initiation of RefundsIOR
- 02 Jun 2025Credit of SharesCOS
- 03 Jun 2025Listing dateLID
Astonea Labs IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retain Minimum | 1 | 1000 | ₹135,000 |
| Retain Maximum | 1 | 1000 | ₹135,000 |
| HNI Minimum | 2 | 2000 | ₹270,000 |
Astonea Labs IPO Reservation
Promoter Holding
Documents
Astonea Labs IPO Valuations
Astonea Labs Limited Financial Information
| Period Ended | 31 Dec 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 96.52 | 80.89 | 64.28 | 52.91 |
| Revenue | 69.69 | 80.29 | 67.26 | 30.17 |
| Profit After Tax | 4.10 | 3.81 | 0.67 | 0.25 |
| Net Worth | 17.28 | 11.97 | 8.16 | 7.49 |
| Reserves and Surplus | 9.56 | 4.37 | 4.16 | 3.49 |
| Total Borrowing | 49.48 | 42.40 | 35.99 | 29.52 |
| Amount in ₹ Crore | ||||
About Astonea Labs IPO
Incorporated in 2017, Astonea Labs Ltd. is engaged in contract manufacturing of pharmaceutical and cosmetic products for companies both within India and internationally.
The company manufactures and markets a variety of pharmaceutical and cosmetic products, including antibiotics, anti-cold medicines, antihistamines, and treatments for diabetes, heart, gynecological issues, infections, and more.
The company offers skin, tooth, and hair care products in forms like gels, creams, and serums, and also trades packaging and raw materials for pharmaceutical and cosmetic industries, meeting industry standards.
The company engages in contract manufacturing of pharmaceutical and cosmetic products, markets its own brands "Glow Up" and "Regero," plans to launch "Avicel," and exports to countries like Iraq and Yemen.
Produts and Offerings:
- Products under our own brands: The company markets “Glow Up” skincare and “Regero” pharma products, offering diverse affordable solutions.
- Products under contract manufacturing: The company provides pharmaceutical and cosmetic products under contract manufacturing, primarily for domestic and export markets.
As of August 16, 2024, the company had 217 employees on payroll.
Strength Of Astonea Labs IPO
1. Our experienced management and dedicated employee base.
2. Scalable business model.
3. Wide and diverse range of product offerings.
4. Quality Service.
Risk Of Astonea Labs IPO
1. The Company has not satisfied the annual OMFUA, under which the FDA assesses and collects fees from qualifying manufacturers of OTC monograph drugs which is mandatory to be paid by all the manufacturers of OTC drugs.
2. There have been some instances of delayed and non-filings in the past with the Registrar of Companies which may attract penalties.
3. The company is dependent on third parties for the supply of raw materials and such third parties could fails in meeting their obligations, which may have a material adverse effect on its business, results of operations and financial condition. Further its 35.47%, 41.96%, 55.74% and 33.90% of its total purchases are derived from its top 10 suppliers for Financial Years ended on March 31, 2024, March 31, 2023, March 31, 2022 and for the period ended December 31, 2024 respectively.
4. The Company, its Promoters, Directors, and Group Companies are party to certain legal proceedings. Any adverse outcome in such proceedings may have an adverse impact on its reputation, business, financial condition, results of operations, and cash flows.
5. Its business is significantly dependent on the revenue generated by manufacturing and selling the pharmaceuticals, which constitutes a substantial portion of its sales and such dependence exposes it to various risks that could materially affect its business operations, financial condition, and results of operations.
6. The company has had negative cash flows in the past. Sustained negative cash flow could adversely impact its business, financial condition, and results of operations.
7. Major revenue of the Company is generated from contract manufacturing and any adverse factors affecting the outsourcing of manufacturing by its customers could have an adverse on its business, results of operations and financial condition.
8. One of its domain names is registered under the name Astonea Foundation. Any dispute with the Astonea Foundation or other unforeseen circumstance may lead to loss of its online presence which could adversely affect its business.
9. The company does not have any long-term contracts with its suppliers. Any shortfall in the supply of its raw materials or an increase in its raw material costs, or other input costs, may adversely affect the pricing and supply of its products and have an adverse effect on its business, results of operations and financial condition.
10. The company has certain contingent liabilities which if materialized, could adversely affect its financial condition.
Objectives Astonea Labs IPO
1. Funding of expenses proposed to be incurred towards registration in Bolivia, South America
2. Purchase and installation of plant and machineries for ointment production for the purpose of export in accordance with the international standards and protocols, on the 2nd floor of the Existing Premises
3. Advertising, marketing and brand building
4. Investment in procuring hardware and software
5. Funding of working capital requirements
6. General corporate purposes
Company Contact Details
Astonea Labs Ltd
SCO 186-187, 2nd Floor, Cabin No. 206, SECTOR 8 C, Sector 8, Chandigarh 160009, India
Phone: +91 9888302323
Email: cs@astonea.org
Website: https://www.astonea.org/
Registrar Contact Details
Lead Mangers
Oneview Corporate Advisors Pvt. Ltd.
Market Maker
Basan Equity Broking